CONMED Co. (NYSE:CNMD) Stock Holdings Lifted by Osterweis Capital Management Inc.

Osterweis Capital Management Inc. lifted its stake in CONMED Co. (NYSE:CNMD - Free Report) by 93.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 186,970 shares of the company's stock after buying an additional 90,505 shares during the quarter. Osterweis Capital Management Inc. owned approximately 0.61% of CONMED worth $12,796,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the stock. HighTower Advisors LLC increased its stake in shares of CONMED by 4.1% during the third quarter. HighTower Advisors LLC now owns 7,056 shares of the company's stock worth $512,000 after purchasing an additional 275 shares in the last quarter. Stifel Financial Corp raised its holdings in CONMED by 13.8% in the 3rd quarter. Stifel Financial Corp now owns 30,675 shares of the company's stock valued at $2,206,000 after acquiring an additional 3,712 shares during the last quarter. Geode Capital Management LLC raised its holdings in CONMED by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 693,400 shares of the company's stock valued at $49,879,000 after buying an additional 8,274 shares during the period. Principal Financial Group Inc. boosted its position in shares of CONMED by 4.2% during the 3rd quarter. Principal Financial Group Inc. now owns 620,715 shares of the company's stock worth $44,631,000 after purchasing an additional 25,047 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of CONMED by 93.6% in the fourth quarter. GAMMA Investing LLC now owns 726 shares of the company's stock valued at $50,000 after buying an additional 351 shares in the last quarter.

CONMED Price Performance

NYSE CNMD traded up $0.31 during mid-day trading on Tuesday, hitting $47.97. The stock had a trading volume of 73,799 shares, compared to its average volume of 461,584. CONMED Co. has a 52-week low of $46.00 and a 52-week high of $78.58. The company has a market cap of $1.48 billion, a price-to-earnings ratio of 11.31, a P/E/G ratio of 1.83 and a beta of 1.28. The company has a 50 day simple moving average of $58.07 and a 200 day simple moving average of $65.55. The company has a quick ratio of 1.06, a current ratio of 2.30 and a debt-to-equity ratio of 0.94.

CONMED (NYSE:CNMD - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.14. CONMED had a return on equity of 14.31% and a net margin of 10.13%. Equities analysts forecast that CONMED Co. will post 4.35 EPS for the current fiscal year.

CONMED Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 4th. Stockholders of record on Friday, March 14th were paid a dividend of $0.20 per share. The ex-dividend date was Friday, March 14th. This represents a $0.80 annualized dividend and a dividend yield of 1.67%. CONMED's dividend payout ratio is presently 18.87%.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Needham & Company LLC lowered their target price on CONMED from $97.00 to $91.00 and set a "buy" rating for the company in a research note on Thursday, February 6th. Stifel Nicolaus boosted their price target on shares of CONMED from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. downgraded CONMED from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $85.00 to $70.00 in a report on Thursday, February 6th. Finally, Wells Fargo & Company lowered their target price on shares of CONMED from $74.00 to $70.00 and set an "equal weight" rating on the stock in a research report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $77.20.

CONMED Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.